Merck and Bio-Techne have agreed that Merck will acquire Bio-Techne for $73 per share, representing a total enterprise value of approximately $11.3 billion.  “This transaction is an important milestone towards delivering on our mid- to long-term strategic agenda. Bio-Techne is an outstanding fit that directly supports our strategic direction focused on delivering cutting-edge products and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!